Next Article in Journal
Immunohistochemistry for Skin Cancers: A Comprehensive Approach to the Diagnosis of Squamous Cell Carcinoma
Next Article in Special Issue
Effects of DHA Oral Supplementation on Plasma Resolvin D1 and D2 Levels in Naïve Breast Cancer Patients
Previous Article in Journal
The Basis for Targeting the Tumor Macrophage Compartment in Glioblastoma Immunotherapy
Previous Article in Special Issue
The Role of Engagement in Virtual Reality to Enhance Emotional Well-Being in Breast Cancer Patients: A Mediation Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 10
10.3390/cancers17101633
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Cancers 2024, 16(20), 3517.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Mukherjee, A.; Bandyopadhyay, D. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody–Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Cancers 2024, 16, 3517

by
Attrayo Mukherjee
1 and
Debasish Bandyopadhyay
2,3,*
1
School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Patia, Bhubaneswar 751024, Odisha, India
2
School of Integrative Biological and Chemical Sciences (SIBCS), University of Texas Rio Grande Valley, Edinburg, TX 78539, USA
3
School of Earth, Environmental, and Marine Sciences (SEEMS), University of Texas Rio Grande Valley, Edinburg, TX 78539, USA
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(10), 1633; https://doi.org/10.3390/cancers17101633
Submission received: 25 April 2025 / Accepted: 30 April 2025 / Published: 12 May 2025
(This article belongs to the Special Issue New Perspectives in the Management of Breast Cancer)
Versions Notes
In the original publication [1], there are three typographical errors (naming errors). Two are in Table 1, and one is in the text (Section 5.4.) as published. The corrected names are written below.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Position in the PublicationAs Appeared in the PublicationTo Be Read as
Table 1. Entry 7, Column 2TrastuzumabDolasynthen B7-H4 Directed ADC
Table 1. Entry 7, Column 3Auristatin hydroxypropylamide (dolasynthen)Auristatin F-Hydroxypropylamide
Section 5.4.Trastuzumab-dolasynthenDolasynthen B7-H4 Directed ADC

Reference

  1. Mukherjee, A.; Bandyopadhyay, D. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody–Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Cancers 2024, 16, 3517. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mukherjee, A.; Bandyopadhyay, D. Correction: Mukherjee, A.; Bandyopadhyay, D. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody–Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Cancers 2024, 16, 3517. Cancers 2025, 17, 1633. https://doi.org/10.3390/cancers17101633

AMA Style

Mukherjee A, Bandyopadhyay D. Correction: Mukherjee, A.; Bandyopadhyay, D. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody–Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Cancers 2024, 16, 3517. Cancers. 2025; 17(10):1633. https://doi.org/10.3390/cancers17101633

Chicago/Turabian Style

Mukherjee, Attrayo, and Debasish Bandyopadhyay. 2025. "Correction: Mukherjee, A.; Bandyopadhyay, D. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody–Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Cancers 2024, 16, 3517" Cancers 17, no. 10: 1633. https://doi.org/10.3390/cancers17101633

APA Style

Mukherjee, A., & Bandyopadhyay, D. (2025). Correction: Mukherjee, A.; Bandyopadhyay, D. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody–Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Cancers 2024, 16, 3517. Cancers, 17(10), 1633. https://doi.org/10.3390/cancers17101633

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop